In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.
Global biopharmaceutical company Mallinckrodt plc announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar Gel (repository corticotropin injection) in patients with refractory rheumatoid arthritis (RA) that did not adequately respond to standard-of-care therapies.
Johnson & Johnson said the company’s Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.
Evidence continues to build for long-lasting immunity to Covid-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.
AstraZeneca is likely to run an additional global trial to assess the efficacy of the company’s Covid-19 vaccine using a lower dosage, the British drugmaker’s chief executive was quoted as saying amid questions over the results of a late-stage study.